News coverage about BiondVax Pharmaceuticals (NASDAQ:BVXV) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. BiondVax Pharmaceuticals earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 50.3008749942632 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the company’s share price in the immediate future.
BiondVax Pharmaceuticals (NASDAQ:BVXV) traded up $0.46 during midday trading on Thursday, reaching $5.98. 24,600 shares of the company traded hands, compared to its average volume of 16,500. BiondVax Pharmaceuticals has a 52-week low of $3.65 and a 52-week high of $10.75. The stock has a market capitalization of $36.07, a price-to-earnings ratio of -3.99 and a beta of 0.33.
Separately, ValuEngine lowered shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
ILLEGAL ACTIVITY NOTICE: “BiondVax Pharmaceuticals (BVXV) Given Daily News Sentiment Rating of 0.03” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3125761/biondvax-pharmaceuticals-bvxv-given-daily-news-sentiment-rating-of-0-03.html.
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.